Stevanato Group S.p.A. closed at $13.57 on Nov 6, up 2.73%, within 2.7% of its 52-week closing low. Volume of 1.4M shares was 1.31× its 20-day average (above normal).
Split-adjusted performance: -29.4% over one month, -25.6% over six months, -45.7% over one year.
Short interest was 966.0K shares at the Oct 15 settlement, down 11.5% from the prior report (0.3% of float, 3.0 days to cover).
No reported quarters with price history yet.
Not enough peers to rank
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
